Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab for Inflammatory Bowel Disease (Prospective Cohort, Multi-omics)
ChiCTR2500113599Phase 4Not yet recruiting
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of guselkumab in Crohn's disease, autoimmune colitis and inflammatory bowel disease (IBD) (3 cohorts), sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoints: Clinical response rate and Clinical remission rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's diseaseautoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on ChiCTR2500113599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500113599.